ICYMI, some of the content featured this week includes a new episode of our podcast discussing maskne, and stories on a lack of skin of color patients in psoriasis trials, how age influences choice of rosacea therapies, learning to navigate teledermatology during a pandemic, plus more.
In case you missed it, some of this week’s featured content includes a new episode of our editorial-hosted podcast, The Cutaneous Connection, discussing maskne with Amir Karam, M.D. Also, this week’s featured articles include stories on cleansing challenges, a lack of skin of color patients in psoriasis trials, how age influences choice of rosacea therapies, learning to navigate teledermatology during a pandemic, plus more.
This week’s edition of The Mainstream Patient features stories about an antibacterial bee by-product popping up in skincare, how sun damage presents itself on different skin types, tips on how to manage hormonal acne caused by menopause, plus more.
Dupilumab and JAK inhibitors are leading the way in atopic dermatitis treatment, but there are numerous clinical trials of both new biologics and new small molecule drugs, and future treatment regimens likely will utilize both.
A majority of psoriasis patients in phase 3 clinical trials for biologics are white, says authors of a recent study. As ethnicity and race may play a role in response to biologics, researchers emphasize need for more diversity in clinical trials.
Joel Schlessinger, M.D., and Adam Friedman, M.D., detail how they have adapted to teledermatology since the start of the COVID-19 pandemic.
Zoe Diana Draelos, M.D., outlines some challenges encountered while cleansing the skin, and answers questions about hand washing hygiene and microbiome cleansing products.
Amir Karam, M.D., facial plastic surgeon, San Diego, Calif., explains the rising incidences of acne associated with face mask usage, otherwise known as maskne, as well as tips for prevention and treatment.
A recent study conducted by the National Rosacea Society reveals more rosacea patients are satisfied with their treatment but highlights the need for treatment option awareness among older patient populations.
Spironolactone demonstrated notable safety and tolerability in females aged <21 years with refractory acne, according to a recent study from the Mayo Clinic.